<DOC>
	<DOCNO>NCT02117791</DOCNO>
	<brief_summary>This local , prospective , non-interventional , multi-center study include patient treat Riociguat inoperable CTEPH ( Chronic thromboembolic pulmonary hypertension ) / persistent recurrent CTEPH surgical treatment . It plan include total 400 patient ( valid safety analysis ) . This study perform all-case investigation . The treatment Riociguat perform base product label Japan . The standard observation period 12 month 1st treatment Riociguat . Safety effectiveness evaluate 4th 12th month . In addition , extension observation carry year 7 year longest collect information safety effectiveness long Riociguat treatment continue . When treatment Riociguat terminate , observation patient end . For patient , investigator record data define protocol evaluation point use Electronic Data Capture ( EDC ) system . The duration study approximately 9 year launch .</brief_summary>
	<brief_title>Prospective , Non-interventional , Multi-center Post-authorization Safety Study Riociguat Chronic Thromboembolic Pulmonary Hypertension ( CTEPH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patients treat Riociguat CTEPH Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Riociguat , Adempas , sGC stimulator , CTEPH , Japan , PMS</keyword>
</DOC>